サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794671

肺塞栓症治療薬の世界市場

Pulmonary Embolism Therapeutics

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
肺塞栓症治療薬の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺塞栓症治療薬の世界市場は2030年までに406億米ドルに達する見込み

2024年に221億米ドルと推定される肺塞栓症治療薬の世界市場は、2024～2030年の分析期間においてCAGR 10.7%で成長し、2030年には406億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口投与は、CAGR 12.0%を記録し、分析期間終了時には272億米ドルに達すると予測されます。非経口投与セグメントの成長率は、分析期間中CAGR 8.2%と推定されます。

米国市場は60億米ドルと推定、中国はCAGR14.7％で成長予測

米国の肺塞栓症治療薬市場は2024年に60億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに85億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.5％と9.5％と予測されています。欧州では、ドイツがCAGR約8.4%で成長すると予測されています。

世界の肺塞栓症治療薬市場- 主要動向と促進要因まとめ

なぜ肺塞栓症治療が急性期医療と予防医療の枠組みで優先されるようになったのか？

血栓による肺動脈の閉塞を特徴とする肺塞栓症（PE）は、世界的に最も生命を脅かす心血管救急疾患の1つです。罹患率や死亡率が高いにもかかわらず、肺塞栓症は無症候性エピソードから突然死まで多様な臨床像を示すため、しばしば過小診断されています。画像診断技術の進歩、診断アルゴリズムの改善、臨床意識の向上により、発生率は上昇傾向にあり、段階的かつ特異的な治療オプションが必要とされています。

PEの管理は、急性期の介入、安定化、長期的な再発予防にわたる。治療レジメンは、PESI（肺塞栓症重症度指数）のようなリスク層別化モデルによって決定され、入院治療が必要か外来治療が必要かを決定します。高リスクのPE患者、特に血行動態が不安定な患者は、全身的血栓溶解療法やカテーテル直接血栓溶解療法で管理されることが多いです。ほとんどの低リスクから中リスクの症例に対する標準治療には、低分子ヘパリン（LMWH）、直接経口抗凝固薬（DOAC）、未分画ヘパリン（UFH）などの薬剤による抗凝固療法が含まれます。

現在の治療状況を形成している薬剤クラスと介入技術は？

抗凝固薬は依然として肺塞栓症治療の要です。ワルファリンのような従来のビタミンK拮抗薬から、リバーロキサバン、アピキサバン、エドキサバンのようなDOACへの移行は、固定投与、モニタリングの軽減、食事との相互作用の減少をもたらし、外来管理を一変させました。これらの薬剤は現在、非大量PE症例の大部分に使用され、同等の有効性と優れた安全性プロファイルが実証されています。LMWHは、病院での初期治療や、がん患者や妊婦などの特殊な集団では、依然として広く使用されています。

血栓溶解療法は血栓溶解に有効であるが、出血のリスクが大きいため、一般的には右室機能障害を伴う高リスクのPEに限られています。EKOS血管内システムなどの新しいカテーテル指向性血栓溶解システムは、標的血栓溶解薬を血栓に直接投与し、全身への影響を最小限に抑えます。機械的血栓除去装置は、出血リスクを軽減しながら大きな血栓を除去するために、一部の症例で導入されています。下大静脈（IVC）フィルターは、合併症のために論議を呼んでいるが、抗凝固療法が禁忌の患者に時折使用されています。薬物療法と介入療法を組み合わせたハイブリッドプロトコールの開発は、ますます一般的になってきています。

臨床ガイドライン、患者層別化、医療システムのプロトコールは市場動向にどのような影響を与えているか？

米国胸部専門医学会（ACCP）、欧州心臓病学会（ESC）、National Institute for Health and Care Excellence（NICE）などの団体による最新の臨床ガイドラインは、早期退院、外来患者管理、個別化された治療計画に重点を置いています。これらのプロトコールは、D-ダイマー測定、CT肺血管造影、ポイントオブケア超音波などの診断ツールの進歩を反映しており、迅速なリスク評価とトリアージが容易になっています。また、病院におけるPE対応チーム（PERT）の出現は、多職種が集まって個別ケアを最適化することで、意思決定に変革をもたらしつつあります。

さらに、医療システムは抗凝固薬の投与量追跡、アドヒアランスモニタリング、遠隔医療相談などのデジタルツールを導入しており、特に慢性PEや退院後の環境において重要です。ICOPER（International Cooperative Pulmonary Embolism Registry）やRIETEのようなレジストリは、治療結果に関する貴重な実データを提供し、エビデンスに基づいて治療基準を改善する指針となっています。特に、外科手術やバルーン肺血管形成術の介入が必要となる慢性血栓塞栓性肺高血圧症（CTEPH）などの長期合併症に注意が向けられています。

世界の肺塞栓症治療薬市場の成長を促進する要因は？

世界の肺塞栓症治療薬市場の成長は、血栓塞栓イベントの発生率の増加、DOACの採用率の上昇、インターベンション技術の拡大によってもたらされます。座りがちなライフスタイル、肥満、悪性腫瘍、術後合併症などが静脈血栓塞栓症（VTE）の負担増に寄与しており、PEは世界の緊急入院の大きな割合を占めています。ヘルスケア専門家と患者の意識の向上により、早期発見と幅広い治療が可能になりました。

医薬品の技術革新は引き続き市場の拡大を形成しています。第XI因子および第XII因子の経路を標的とするパイプライン候補は、出血性合併症を最小限に抑えながら血栓リスクを低減することを目指しており、脆弱な集団に対する治療選択肢をさらに改善する可能性があります。さらに、AIを活用した診断ツールや予測分析プラットフォームが、高リスク者を積極的に特定するためにテストされています。新興経済諸国におけるヘルスケアインフラの開発は、タイムリーなPEの診断と管理へのアクセスを拡大しています。

主な業界参加企業は、バイエルAG、ブリストル・マイヤーズスクイブ、ファイザー、ベーリンガーインゲルハイム、ジョンソン・エンド・ジョンソン（ヤンセン）、イナリ・メディカル、ペナンブラ・インクなどです。製薬企業と医療機器企業の戦略的パートナーシップは、治療と介入ケアモデルの統合を加速させています。リスク層別化プロトコル、外来患者管理、精密医療のアプローチが成熟するにつれて、肺塞栓症治療薬市場は薬理学的領域と手技的領域の双方で力強い成長を遂げる態勢が整っています。

セグメント

投与経路（経口投与、非経口投与）;アプリケーション（病院、外来手術センター、研究機関）

調査対象企業の例

  • Acticor Biotech SAS
  • Anthos Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.（Roche subsidiary）
  • Gilead Sciences, Inc.
  • Inari Medical, Inc.
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.
  • Viatris Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37845

Global Pulmonary Embolism Therapeutics Market to Reach US$40.6 Billion by 2030

The global market for Pulmonary Embolism Therapeutics estimated at US$22.1 Billion in the year 2024, is expected to reach US$40.6 Billion by 2030, growing at a CAGR of 10.7% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach US$27.2 Billion by the end of the analysis period. Growth in the Parenteral Administration segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.0 Billion While China is Forecast to Grow at 14.7% CAGR

The Pulmonary Embolism Therapeutics market in the U.S. is estimated at US$6.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.5 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Pulmonary Embolism Therapeutics Market - Key Trends & Drivers Summarized

Why Is Pulmonary Embolism Therapy Becoming a Priority in Acute and Preventive Care Frameworks?

Pulmonary embolism (PE), characterized by a blockage in the pulmonary arteries due to a blood clot, represents one of the most life-threatening cardiovascular emergencies globally. Despite its high morbidity and mortality rates, PE is frequently underdiagnosed due to its varied clinical presentation, ranging from asymptomatic episodes to sudden death. Advances in imaging techniques, improved diagnostic algorithms, and increased clinical awareness have led to rising incidence rates-necessitating scalable and stage-specific therapeutic options.

The management of PE spans acute intervention, stabilization, and long-term recurrence prevention. Treatment regimens are driven by risk stratification models such as the Pulmonary Embolism Severity Index (PESI), determining whether patients require hospitalization or outpatient care. High-risk PE patients, particularly those with hemodynamic instability, are often managed with systemic thrombolysis or catheter-directed thrombolysis. The standard of care for most low to intermediate-risk cases includes anticoagulant therapy with agents such as low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), or unfractionated heparin (UFH).

Which Drug Classes and Intervention Technologies Are Shaping the Current Treatment Landscape?

Anticoagulants remain the cornerstone of pulmonary embolism therapy. The transition from traditional Vitamin K antagonists like warfarin to DOACs such as rivaroxaban, apixaban, and edoxaban has transformed outpatient management by offering fixed dosing, reduced monitoring, and fewer dietary interactions. These agents are now preferred for the majority of non-massive PE cases and have demonstrated comparable efficacy with better safety profiles. LMWH is still widely used in initial hospital-based care and in special populations such as cancer patients and pregnant women.

Thrombolytic therapy, while effective in dissolving clots, carries a significant risk of bleeding and is generally reserved for high-risk PE with right ventricular dysfunction. Newer catheter-directed thrombolysis systems, such as the EKOS endovascular system, deliver targeted thrombolytics directly to the clot, minimizing systemic exposure. Mechanical thrombectomy devices are being deployed in select cases to remove large clots with reduced hemorrhagic risk. Inferior vena cava (IVC) filters, although controversial due to complications, are occasionally used in patients with contraindications to anticoagulation. The development of hybrid protocols combining pharmacological and interventional therapies is becoming increasingly common.

How Are Clinical Guidelines, Patient Stratification, and Health System Protocols Influencing Market Trends?

Updated clinical guidelines from bodies such as the American College of Chest Physicians (ACCP), European Society of Cardiology (ESC), and National Institute for Health and Care Excellence (NICE) emphasize early discharge, outpatient management, and personalized treatment planning. These protocols reflect advances in diagnostic tools, including D-dimer assays, CT pulmonary angiography, and point-of-care ultrasound, which facilitate rapid risk assessment and triaging. The emergence of PE response teams (PERTs) in hospitals is also transforming decision-making by bringing together multidisciplinary teams to optimize individualized care.

Further, health systems are adopting digital tools for anticoagulant dose tracking, adherence monitoring, and telehealth consultations-especially important in chronic PE or post-discharge settings. Registries such as the International Cooperative Pulmonary Embolism Registry (ICOPER) and RIETE provide valuable real-world data on treatment outcomes and guide evidence-based refinements in care standards. Special attention is being directed toward long-term complications such as chronic thromboembolic pulmonary hypertension (CTEPH), which necessitates surgical or balloon pulmonary angioplasty interventions.

What Factors Are Driving the Growth of the Global Pulmonary Embolism Therapeutics Market?

The growth in the global pulmonary embolism therapeutics market is driven by increasing incidence of thromboembolic events, rising adoption of DOACs, and expansion of interventional technologies. Sedentary lifestyles, obesity, malignancies, and post-operative complications are contributing to the growing burden of venous thromboembolism (VTE), with PE accounting for a significant share of emergency admissions worldwide. Improved awareness among healthcare professionals and patients has led to earlier detection and broader treatment coverage.

Pharmaceutical innovation continues to shape market expansion. Pipeline candidates targeting Factor XI and Factor XII pathways aim to reduce thrombotic risk with minimal bleeding complications, which could further improve treatment options for vulnerable populations. Additionally, AI-powered diagnostic tools and predictive analytics platforms are being tested to identify high-risk individuals proactively. Healthcare infrastructure development in emerging economies is expanding access to timely PE diagnosis and management.

Key industry participants include Bayer AG, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Johnson & Johnson (Janssen), Inari Medical, and Penumbra Inc. Strategic partnerships between pharma and device companies are accelerating the integration of therapeutic and interventional care models. As risk stratification protocols, outpatient management, and precision medicine approaches mature, the pulmonary embolism therapeutics market is poised for robust growth across both pharmacological and procedural domains.

SCOPE OF STUDY:

The report analyzes the Pulmonary Embolism Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Administration, Parenteral Administration); Application (Hospitals Application, Ambulatory Surgery Centers Application, Research Institutes Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Acticor Biotech SAS
  • Anthos Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc. (Roche subsidiary)
  • Gilead Sciences, Inc.
  • Inari Medical, Inc.
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Ltd.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pulmonary Embolism Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cardiopulmonary Disorders Drives Demand for Pulmonary Embolism Therapeutics
    • Expansion of Aging Population Globally Strengthens Business Case for Chronic Care Drugs
    • Innovation in Novel Oral Anticoagulants (NOACs) Enhances Convenience and Adherence
    • Increasing Awareness of Deep Vein Thrombosis Risks Throws the Spotlight on Early Intervention
    • Growth in Diagnostic Imaging Capabilities Supports Rapid and Accurate Therapeutic Initiation
    • Partnerships With Hospital Networks Accelerate Adoption of First-Line Treatment Protocols
    • Surge in Post-COVID Complications Promotes Expanded Use of Pulmonary Anticoagulation Therapies
    • Development of Catheter-Directed Thrombolysis Technologies Spurs Minimally Invasive Treatment Options
    • Regulatory Fast-Tracking for High-Risk Pulmonary Therapeutics Enhances Market Entry Speed
    • Development of AI-Enabled Clinical Decision Support Tools Improves Treatment Planning
    • Advancements in Biomarker Research Support Personalized Antithrombotic Therapy Regimens
    • Rising Use of Direct-to-Consumer Awareness Campaigns Promotes Symptom Recognition and Early Diagnosis
    • Collaborations With Insurance Providers Improve Accessibility to High-Cost Biologic Drugs
    • Expansion of Ambulatory Pulmonary Care Settings Enhances Drug Distribution Beyond Hospitals
    • Growth in Use of Injectable Therapies for Acute PE Cases Supports Hospital-Based Treatment Revenues
    • Focus on Long-Term Prophylaxis Drives R&D in Maintenance Dosing and Extended Therapies
    • Regulatory Reforms on Stroke and PE Co-Management Drive Integrated Care Adoption
    • Entry Into Biosimilars for Established Therapies Strengthens Competitive Pricing Leverage
    • Availability of Combination Therapy Trials Improves Efficacy and Reduces Readmission Rates
    • Institutional Focus on Reducing Mortality and Readmission Sustains Investment in High-Efficacy Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pulmonary Embolism Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pulmonary Embolism Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pulmonary Embolism Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research Institutes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research Institutes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Research Institutes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • CHINA
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Pulmonary Embolism Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Pulmonary Embolism Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Pulmonary Embolism Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Pulmonary Embolism Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • INDIA
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Pulmonary Embolism Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Pulmonary Embolism Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Pulmonary Embolism Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Pulmonary Embolism Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Pulmonary Embolism Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Pulmonary Embolism Therapeutics by Administration Route - Oral Administration and Parenteral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Pulmonary Embolism Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pulmonary Embolism Therapeutics by Application - Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pulmonary Embolism Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Ambulatory Surgery Centers Application and Research Institutes Application for the Years 2014, 2025 & 2030

IV. COMPETITION